One formulation based in active targeting achieved Phase II clinical trials: MM-302, consisting of PEGylated liposomes coated with anti-HER2 (human epidermal growth factor receptor 2), for breast cancer treatment. The gene discussed is ERBB2; the disease is breast carcinoma.